Halozyme Therapeutics

HALO Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$64.49

-1.39% today

52W: $47.50 – $82.22

52W Low: $47.50 Position: 48.9% 52W High: $82.22

🔗 Compare Brokers

Key Metrics

P/E Ratio

25.19x

Price-to-Earnings

Forward P/E

6.55x

Forward Price/Earnings

P/S Ratio

5.47x

Price-to-Sales

EV/EBITDA

10.74x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$7.6B

Market Capitalization

Revenue Growth

51.6%

YoY Revenue Growth

Profit Margin

22.69%

Net profit margin

ROE

153.59%

Return on Equity

Beta

1.03

Market sensitivity

Short Interest

14.96%

% of float sold short

Avg. Volume

1,847,813

Average daily volume

Valuation Analysis

Signal

Fair

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

9 analysts

Avg. Price Target

$84.89

+31.63% upside

Target Range

$56.00 – $96.00

About the Company

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides H

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 423 Exchange: NMS